Drugs / APT-1011
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03191864 | Jun 2017 → Jan 2019 | eosinophilic esophagitis | Adare Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04281108 | Jan 2020 → May 2022 | eosinophilic esophagitis | Ellodi Pharmaceuticals, LP | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05095116 | — | eosinophilic esophagitis | Ellodi Pharmaceuticals, LP | No longer available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-03-12 | Adare Pharmaceuticals, Inc. | Primary End-Point achieved in Phase IIb Study (FLUTE™) for APT-1011 adarepharmasolutions.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APT-1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04281108 ↗ |
| Route | Oral | “APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate” NCT03191864 ↗ |